A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles
| Autor: | Marianne Graflund, György Horvath, Bengt Sorbe, Lisa Nygren |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
myalgia
Cancer Research medicine.medical_specialty Nausea medicine.medical_treatment Neutropenia Gastroenterology chemistry.chemical_compound 3-week administration Internal medicine medicine Mucositis docetaxel weekly administration Chemotherapy non-hematological toxicity business.industry Articles medicine.disease Carboplatin Surgery ovarian cancer Oncology Docetaxel chemistry carboplatin Vomiting medicine.symptom business hematological toxicity medicine.drug |
| Zdroj: | Oncology Letters |
| ISSN: | 1792-1082 1792-1074 |
| DOI: | 10.3892/ol.2013.1146 |
| Popis: | The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8 and 15, and carboplatin (AUC 5) on day 1 or with docetaxel (75 mg/m2) and carboplatin (AUC 5) on day 1; Q21 days for 6 cycles. This study was a pooled study of two primary phase II studies. A total of 108 patients received the weekly schedule and 59 patients received the three-week schedule. All patients were evaluated for toxicity. The overall response rate was 79% and the biochemical response 93% for the weekly schedule. The median overall survival rate was 35.3 months. Neutropenia was significantly more common (ANOVA; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|